-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2629 Hospital-Acquired Venous Thromboembolism (HA-VTE) Epidemiology and Risk Factors Among Critically Ill Children and Young Adults with Diabetic Ketoacidosis

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Epidemiology, Clinical Research, Thromboembolism, Diseases
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Kristin DeMayo, DO1*, Elizabeth Havlicek, DO2*, Maya Root, BS3*, Marisol Betensky, MD, MPH4, Zachary Goldman3*, Neil Goldenberg, MD, PhD3 and Anthony A Sochet, MD, MSc5*

1University of South Florida, Tampa, FL
2University of Utah, Salt Lake City, UT
3Johns Hopkins All Children's Hospital, St. Petersburg, FL
4Johns Hopkins University School of Medicine, Baltimore, MD
5Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, FL

Introduction: Children hospitalized for diabetic ketoacidosis (DKA) experience hyperglycemic hyperosmolarity and severe dehydration that are considered prothrombotic, heightening the risk of hospital-acquired venous thromboembolism (HA-VTE). Yet, the occurrence rate and risk factors for HA-VTE among cases of pediatric DKA remain ill-defined.

Methods: We performed a retrospective, single center cohort study including children and young adults 0 - 21 years of age hospitalized in the pediatric intensive care unit for DKA from Oct 2020 – December 2023. The primary outcome was radiographically confirmed HA-VTE (i.e., pulmonary embolism, limb/neck deep venous thrombosis, and cerebral sinovenous thromboembolism). Detailed data were collected on HA-VTE (timing, location, central venous catheterization [CVC]-relatedness), DKA (degrees of acidosis and hyperglycemia, β-hydroxybutyrate levels, clinical cerebral edema), thromboprophylaxis (TP) modalities, and putative HA-VTE risk factors (age, inherited coagulopathy, acute and chronic immobility, mechanical ventilation [IMV], infectious comorbidity). Descriptive and comparative (e.g., chi-square, student’s t, and Wilcoxon rank sum tests) statistics were performed.

Results: During the study period, 386 children and young adults were hospitalized for DKA of which 2 (0.5%) developed a HA-VTE (both were CVC-related). The children who developed HA-VTE were 13 and 14 years of age, prescribed mechanical TP without pharmacologic TP, treated for acute cerebral edema, profoundly acidotic (β-hydroxybutyrate: 8.5 and 9.6 mmol/L, respectively), acutely immobilized (per Braden QD values), and exhibited plasma hyperosmolarity (339 and 342 mOsm/kg, respectively). Rates of HA-VTE were more common among subpopulations with CVC (40% vs 0%), symptomatic cerebral edema (12.5% vs 0%), undergoing IMV (20% vs 0.2%), and COVID-19 infection (5.6% vs 0.3%) as compared to those without these clinical features.

Conclusion: The observed HA-VTE rate among critically ill children with DKA over a three-year period was 0.5%. Putative risk factors for HA-VTE in this population, including comorbid conditions and markers of disease severity at presentation such as symptomatic cerebral edema, degree of acidosis, CVC, and IMV, should be prospectively investigated.

Disclosures: Betensky: Aziyo: Honoraria; Boston Scientific: Honoraria; Zoll: Honoraria; NHLBI K23: Research Funding; Abbot: Honoraria. Goldenberg: Chiesi: Consultancy; J&J: Consultancy; Pfizer: Consultancy; NHLBI K24: Research Funding; Boehringer Ingelheim: Research Funding; Bayer: Consultancy; Anthos: Consultancy.

*signifies non-member of ASH